Main menu

Native methylation sequencing for analysis of neurodegenerative conditions

  • Published on: March 10 2026

Chad Pollard, CEO of Wasatch Biolabs, describes how the native sequencing capabilities of Oxford Nanopore enabled Wasatch to create new research tools with the potential to change how we understand and detect Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

Authors: Chad Pollard, CEO of Wasatch Biolabs

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
English flag